Rationale and Design for a Multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble Guanylate Cyclase stimulator Praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

ConclusionThe CAPACITY HFpEF trial will provide data on short-term safety and efficacy of praliciguat on peak exercise capacity, as well as multiple secondary endpoints of submaximal functional capacity, patient-reported outcomes, and biomarkers.
Source: American Heart Journal - Category: Cardiology Source Type: research